PAR-1和HIF-1α在乳腺癌新辅助化疗中的表达及其临床意义  

Expression and significance of HIF-1α and PAR-1 in neoadjuvant chemotherapy for breast carcinoma

作　　者：史俊峰[1] 周洪伟[1] 刘慧敏[1] 周士福[1] 

机构地区：[1]无锡市第四人民医院肿瘤外科,214062

出　　处：《江苏医药》2010年第13期1526-1528,共3页Jiangsu Medical Journal

摘　　要：目的分析乏氧诱导因子1(HIF-1α)和蛋白酶活化受体1(PAR-1)在乳腺癌中的表达及在新辅助化疗前后的变化。方法用免疫组化法检测45例乳腺癌患者新辅助化疗前后癌组织中PAR-1、HIF-1α的表达。结果 PAR-1、HIF-1α在乳腺癌组织中的阳性率分别为66.7%、77.8%,化疗后乳腺癌组织中PAR-1表达率明显降低(66.7%vs.40.0%)(P<0.05)。新辅助化疗前、后,PAR-1、HIF-1α在乳腺癌中表达均呈正相关(P<0.05、P<0.01)。结论乳腺癌中存在PAR-1和HIF-1α的过表达,新辅助化疗可以显著降低PAR-1表达率,PAR-1有可能作为预测乳腺癌新辅助化疗疗效的生物学指标。Objective To analyze the expression and significance of hypoxia-inducible factor-1α（HIF-1α） and protease-activated receptor-1（PAR-1） in neoadjuvant chemotherapy for breast carcinoma.Methods Immunohistochemistry was used to detect the expressions of PAR-1 and HIF-1α in 45 cases with breast cancer before and after neoadjuvant chemotherapy.Results Positive rates of PAR-1 and HIF-1α in breast cancer tissues were 66.7% and 77.8%,respectively.Compared to before,positive rate of PAR-1 was decreased after neoadjuvant chemotherapy（66.7% vs. 40.0%）（P0.05）.PAR-1 was positively correlated to HIF-1α in breast cancer before and after neoadjuvant chemotherapy（P0.05 and P0.01）.Conclusion Over-expressions of PAR-1 and HIF-1α exist in breast cancer.Neoadjuvant chemotherapy can significantly reduce the expression of PAR-1,which could be taken as an effective biological marker for predicting efficacy of neoadjuvant chemotherapy for breast cancer.

关 键 词：乳腺癌 新辅助化疗 HIF-1Α PAR-1 

分 类 号：R737[医药卫生—肿瘤]